TABLE 1

HRs of use of statins for incident CVD in patients with type 2 diabetes

Number at riskHR95% CIP
Initiation versus noninitiation of statins during follow-up in 4,599 nonprevalent users (code: yes/no)
    Model 1*1,0790.550.42–0.73<0.0001
    Model 21,0790.610.46–0.800.0003
    Model 31,0790.590.45–0.780.0002
Time-dependent initiation versus noninitiation of statins during follow-up in 4,599 nonprevalent users
    Model 1*1,0791.371.03–1.820.0308
    Model 21,0791.431.08–1.900.0127
    Model 31,0791.411.06–1.880.0179
  • *Model 1 was adjusted for age, sex, BMI, smoking status, alcohol use, LDL cholesterol, HDL cholesterol, triglyceride, systolic blood pressure, A1C, estimated glomerular filtration rate, and Ln (urinary albumin-to-creatinine ratio + 1) at enrollment.

  • †Based on model 1, model 2 was further adjusted for use of gliclazide and rosiglitazone from enrollment to the first date of CVD, death, or censoring, whichever came first, using a forward stepwise algorithm with P = 0.30 for entry and removal.

  • ‡Based on model 2, model 3 was further adjusted for the probability of starting statin therapy, which was calculated using a logistic procedure with independent variables of age, BMI, LDL cholesterol, triglyceride, A1C, systolic blood pressure, Ln (albumin-to-creatinine ratio + 1), duration of diabetes, and retinopathy at enrollment (using the same forward stepwise algorithm).